Novartis Animal Health is pleased to announce major sponsorship of the NSA Welsh Sheep
April 7, 2011 — Leading animal health company demonstrates ongoing support for sheep producers and the wider industry
Novartis Animal Health has once again fulfilled its strong commitment to the sheep industry, and its continued support of the National Sheep Association, with the announcement that it will be a key sponsor of the longstanding NSA Welsh Sheep event this Spring.
The one-day show will be held on Wednesday May 18, 2011, at Maesllwyni Farm, Penegoes, Machynlleth, and is set to provide a wealth of useful technical and business information on a range of key industry issues and provide valuable direction for sheep producers.
“After the successful launch and uptake of ZOLVIX® – the Novartis’ new 4-AD class (monepantel*) wormer – in 2010, the anticipated success of the Welsh Sheep event marks yet another positive step forward for the industry,” says Novartis Animal Health’s Helen Langham.
“With continued investment from Novartis Animal Health in providing forward thinking technical and professional solutions, the future is bright. This Spring is a particularly exciting time with the launch of CLiKZiN® as a complement to our market leading extended duration blowfly prevention product CLiK ® With the season getting longer every year, we recognise the importance of providing a flexible package for sheep farmers and it is anticipated that CLiKZiN®, with it’s short 7 day meat withhold period, will be a welcome addition to our portfolio.
”The NSA Welsh Sheep Event is always unmissable and represents one of our key major sponsorship areas with other similar industry events throughout the UK. Novartis Animal Health are pleased to be able to continue our support of the NSA shows, for the good of sheep producers and the sheep industry as a whole,” adds Miss Langham.
As in previous years, it is anticipated the show will be well-attended and both useful and informative for everyone involved in the industry, from production through to the consumer. There will be wider information available for professionals and affiliated bodies as well as the opportunity to showcase the many and varied aspects of the sheep industry to a wider audience.
About CLiKZiN®
CLiKZiN® is a registered trademark of Novartis AG, Basle, Switzerland. It is the brand name for dicyclanil 1.25% Pour On for sheep and a line extension of CLiK. Advice on the use of this or alternative medicines must be sought from the medicine prescriber. Use medicines responsibly. Legal category: POM-VPS in UK and LM in ROI
About CLiK®
CLiK® Pour on contains 5% (w/v) dicyclanil. CLiK® is a registered trademark of Novartis AG, Basle, Switzerland. Advice on the use of this or alternative medicines must be sought from the medicine prescriber. Use medicines responsibly. Legal Category: POM-VPS in UK and LM in ROI
About ZOLVIX®
ZOLVIX® contains 25g/l monepantel. ZOLVIX® is a registered trademark and OPTIMUMTM, OPTIVIXTM and OPTILINETM are trademarks of Novartis AG, Basel Switzerland. Advice on this or the use of alternative medicines must be sought from the medicine prescriber. Use medicines responsibly. Legal category: POM-V (united Kingdom), POM (Ireland).
END
About Novartis Animal Health
Novartis Animal Health researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Headquartered in Basel, Switzerland and present in almost 40 countries, Novartis Animal Health employs about 2,700 people worldwide. For more information, please visit www.ah.novartis.com
For farm animals, we specialise in offering the products CliK, Rycoben and the Fasinex range of Flukicides that aid in the prevention of losses associated with Fly, Fluke and Worm infestations in both Sheep and Cattle.
About Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2010, the Group’s continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates (including 16,700 Alcon associates) and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
For further information, contact:
Novartis Press Office +44 (0) 1276 698691
Helen Langham, Novartis Animal Health – 01276 694402
Kendalls Communications – 01394 610022
.
